KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Depreciation and Depletion: 2019-2024

Historic Depreciation and Depletion for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Dec 2024 value amounting to $18.3 million.

  • Recursion Pharmaceuticals' Depreciation and Depletion rose 47.62% to $6.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was $18.3 million, marking a year-over-year increase of 14.38%. This contributed to the annual value of $18.3 million for FY2024, which is 15.09% up from last year.
  • According to the latest figures from FY2024, Recursion Pharmaceuticals' Depreciation and Depletion is $18.3 million, which was up 15.09% from $15.9 million recorded in FY2023.
  • In the past 5 years, Recursion Pharmaceuticals' Depreciation and Depletion registered a high of $18.3 million during FY2024, and its lowest value of $4.2 million during FY2020.
  • Moreover, its 3-year median value for Depreciation and Depletion was $15.9 million (2023), whereas its average is $15.2 million.
  • Data for Recursion Pharmaceuticals' Depreciation and Depletion shows a peak YoY spiked of 109.52% (in 2021) over the last 5 years.
  • Recursion Pharmaceuticals' Depreciation and Depletion (Yearly) stood at $4.2 million in 2020, then soared by 109.52% to $8.8 million in 2021, then increased by 29.55% to $11.4 million in 2022, then soared by 39.47% to $15.9 million in 2023, then climbed by 15.09% to $18.3 million in 2024.